Stan Smith Purchases 33,333 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) Director Stan Smith acquired 33,333 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were bought at an average price of $1.50 per share, with a total value of $49,999.50. Following the acquisition, the director now directly owns 1,305,059 shares of the company's stock, valued at $1,957,588.50. The trade was a 2.62% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

MAIA Biotechnology Price Performance

NYSEAMERICAN:MAIA traded down $0.15 on Friday, reaching $1.80. 315,261 shares of the company's stock were exchanged, compared to its average volume of 216,363. The firm has a market cap of $47.09 million, a price-to-earnings ratio of -1.30 and a beta of 0.20. MAIA Biotechnology, Inc. has a 52 week low of $1.40 and a 52 week high of $4.24. The stock has a fifty day simple moving average of $1.79 and a 200-day simple moving average of $2.07.

Hedge Funds Weigh In On MAIA Biotechnology

An institutional investor recently bought a new position in MAIA Biotechnology stock. Jane Street Group LLC bought a new stake in shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 39,057 shares of the company's stock, valued at approximately $77,000. Jane Street Group LLC owned about 0.15% of MAIA Biotechnology at the end of the most recent reporting period. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.